Vascular endothelial growth factor and diabetic retinopathy: Role of oxidative stress

Ruth B Caldwell, Manuela Bartoli, M. Ali Behzadian, Azza E.B. El-Remessy, Mohamed Al-Shabrawey, Daniel H. Platt, Gregory I Liou, Robert William Caldwell

Research output: Contribution to journalReview article

172 Citations (Scopus)

Abstract

Retinal neovascularization and macular edema are central features of diabetic retinopathy, a major cause of blindness in working age adults. The currently established treatment for diabetic retinopathy targets the vascular pathology by laser photocoagulation. This approach is associated with significant adverse effects due the destruction of neural tissue and is not always effective. Characterization of the molecular and cellular processes involved in vascular growth and hyperpermeability has led to the recognition that the angiogenic growth factor and vascular permeability factor VEGF (vascular endothelial growth factor) play a pivotal role in the retinal microvascular complications of diabetes. Thus, VEGF represents an important target for therapeutic intervention in diabetic retinopathy. Agents that directly inhibit the actions of VEGF and its receptors show considerable promise, but have not proven to be completely effective in blocking pathological angiogenesis. Therefore, a better understanding of the molecular events that control VEGF expression and mediate its downstream actions is important to define more precise therapeutic targets for intervention in diabetic retinopathy. This review highlights the current understanding of the process by which VEGF gene expression is regulated and how VEGF's biological effects are altered during diabetes. In particular, cellular and molecular alterations seen in diabetic models are considered in the context of high glucose-mediated oxidative stress effects on VEGF expression and action. Potential therapeutic strategies for preventing VEGF overexpression or blocking its pathological actions in the diabetic retina are considered.

Original languageEnglish (US)
Pages (from-to)511-524
Number of pages14
JournalCurrent Drug Targets
Volume6
Issue number4
DOIs
StatePublished - Jun 1 2005

Fingerprint

Oxidative stress
Diabetic Retinopathy
Vascular Endothelial Growth Factor A
Oxidative Stress
Medical problems
Blood Vessels
Pathologic Neovascularization
Retinal Neovascularization
Papilledema
Vascular Endothelial Growth Factor Receptor
Macular Edema
Light Coagulation
Angiogenesis Inducing Agents
Pathology
Diabetes Complications
Blindness
Therapeutics
Gene expression
Retina
Intercellular Signaling Peptides and Proteins

Keywords

  • Diabetes
  • Diabetic retinopathy
  • Drug therapy
  • High glucose
  • Hyperglycemia
  • Oxidative stress
  • VEGF

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Vascular endothelial growth factor and diabetic retinopathy : Role of oxidative stress. / Caldwell, Ruth B; Bartoli, Manuela; Behzadian, M. Ali; El-Remessy, Azza E.B.; Al-Shabrawey, Mohamed; Platt, Daniel H.; Liou, Gregory I; Caldwell, Robert William.

In: Current Drug Targets, Vol. 6, No. 4, 01.06.2005, p. 511-524.

Research output: Contribution to journalReview article

@article{7e8d663624004238b113c5000090e33c,
title = "Vascular endothelial growth factor and diabetic retinopathy: Role of oxidative stress",
abstract = "Retinal neovascularization and macular edema are central features of diabetic retinopathy, a major cause of blindness in working age adults. The currently established treatment for diabetic retinopathy targets the vascular pathology by laser photocoagulation. This approach is associated with significant adverse effects due the destruction of neural tissue and is not always effective. Characterization of the molecular and cellular processes involved in vascular growth and hyperpermeability has led to the recognition that the angiogenic growth factor and vascular permeability factor VEGF (vascular endothelial growth factor) play a pivotal role in the retinal microvascular complications of diabetes. Thus, VEGF represents an important target for therapeutic intervention in diabetic retinopathy. Agents that directly inhibit the actions of VEGF and its receptors show considerable promise, but have not proven to be completely effective in blocking pathological angiogenesis. Therefore, a better understanding of the molecular events that control VEGF expression and mediate its downstream actions is important to define more precise therapeutic targets for intervention in diabetic retinopathy. This review highlights the current understanding of the process by which VEGF gene expression is regulated and how VEGF's biological effects are altered during diabetes. In particular, cellular and molecular alterations seen in diabetic models are considered in the context of high glucose-mediated oxidative stress effects on VEGF expression and action. Potential therapeutic strategies for preventing VEGF overexpression or blocking its pathological actions in the diabetic retina are considered.",
keywords = "Diabetes, Diabetic retinopathy, Drug therapy, High glucose, Hyperglycemia, Oxidative stress, VEGF",
author = "Caldwell, {Ruth B} and Manuela Bartoli and Behzadian, {M. Ali} and El-Remessy, {Azza E.B.} and Mohamed Al-Shabrawey and Platt, {Daniel H.} and Liou, {Gregory I} and Caldwell, {Robert William}",
year = "2005",
month = "6",
day = "1",
doi = "10.2174/1389450054021981",
language = "English (US)",
volume = "6",
pages = "511--524",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Vascular endothelial growth factor and diabetic retinopathy

T2 - Role of oxidative stress

AU - Caldwell, Ruth B

AU - Bartoli, Manuela

AU - Behzadian, M. Ali

AU - El-Remessy, Azza E.B.

AU - Al-Shabrawey, Mohamed

AU - Platt, Daniel H.

AU - Liou, Gregory I

AU - Caldwell, Robert William

PY - 2005/6/1

Y1 - 2005/6/1

N2 - Retinal neovascularization and macular edema are central features of diabetic retinopathy, a major cause of blindness in working age adults. The currently established treatment for diabetic retinopathy targets the vascular pathology by laser photocoagulation. This approach is associated with significant adverse effects due the destruction of neural tissue and is not always effective. Characterization of the molecular and cellular processes involved in vascular growth and hyperpermeability has led to the recognition that the angiogenic growth factor and vascular permeability factor VEGF (vascular endothelial growth factor) play a pivotal role in the retinal microvascular complications of diabetes. Thus, VEGF represents an important target for therapeutic intervention in diabetic retinopathy. Agents that directly inhibit the actions of VEGF and its receptors show considerable promise, but have not proven to be completely effective in blocking pathological angiogenesis. Therefore, a better understanding of the molecular events that control VEGF expression and mediate its downstream actions is important to define more precise therapeutic targets for intervention in diabetic retinopathy. This review highlights the current understanding of the process by which VEGF gene expression is regulated and how VEGF's biological effects are altered during diabetes. In particular, cellular and molecular alterations seen in diabetic models are considered in the context of high glucose-mediated oxidative stress effects on VEGF expression and action. Potential therapeutic strategies for preventing VEGF overexpression or blocking its pathological actions in the diabetic retina are considered.

AB - Retinal neovascularization and macular edema are central features of diabetic retinopathy, a major cause of blindness in working age adults. The currently established treatment for diabetic retinopathy targets the vascular pathology by laser photocoagulation. This approach is associated with significant adverse effects due the destruction of neural tissue and is not always effective. Characterization of the molecular and cellular processes involved in vascular growth and hyperpermeability has led to the recognition that the angiogenic growth factor and vascular permeability factor VEGF (vascular endothelial growth factor) play a pivotal role in the retinal microvascular complications of diabetes. Thus, VEGF represents an important target for therapeutic intervention in diabetic retinopathy. Agents that directly inhibit the actions of VEGF and its receptors show considerable promise, but have not proven to be completely effective in blocking pathological angiogenesis. Therefore, a better understanding of the molecular events that control VEGF expression and mediate its downstream actions is important to define more precise therapeutic targets for intervention in diabetic retinopathy. This review highlights the current understanding of the process by which VEGF gene expression is regulated and how VEGF's biological effects are altered during diabetes. In particular, cellular and molecular alterations seen in diabetic models are considered in the context of high glucose-mediated oxidative stress effects on VEGF expression and action. Potential therapeutic strategies for preventing VEGF overexpression or blocking its pathological actions in the diabetic retina are considered.

KW - Diabetes

KW - Diabetic retinopathy

KW - Drug therapy

KW - High glucose

KW - Hyperglycemia

KW - Oxidative stress

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=21444439235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21444439235&partnerID=8YFLogxK

U2 - 10.2174/1389450054021981

DO - 10.2174/1389450054021981

M3 - Review article

C2 - 16026270

AN - SCOPUS:21444439235

VL - 6

SP - 511

EP - 524

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 4

ER -